顾崇怀,赵昕,邓宇阳,荆全民,王效增,马颖艳,刘海伟,徐凯,王斌,韩雅玲

• 1:沈阳军区总医院心内科
• 2:安庆市立医院心血管内科

摘要(Abstract)：

目的评估比伐芦定应用于急性心肌梗死患者行直接经皮冠状动脉介入治疗(PCI)靶血管开通后再灌注血流恢复情况。方法入选2012年5月至2015年4月于沈阳军区总医院接受直接PCI治疗的急性心肌梗死患者245例,依据直接PCI术中用药分为比伐芦定组122例和普通肝素组123例。主要观察指标为冠状动脉造影显示TIMI血栓分级(TIMI thrombus grade)、直接PCI靶血管开通后即刻TIMI(thrombolysis in myocardial infarction)血流、校正TIMI帧数(corrected TIMI frame count,CTFC)及住院期间、出院后30 d、随访1年的净临床不良事件(NACE)、主要不良心血管事件(MACE)及美国出血学术研究联合会出血标准(BARC)出血事件。结果与普通肝素组患者相比,比伐芦定组患者入院平均心率较快[(79.28±15.75)次/min比(75.38±12.75)次/min,P=0.034]。而其他一般资料、实验室指标及介入治疗资料等方面两组间比较,差异均无统计学意义(均P>0.05)。靶血管开通后,无论应用TIMI血流评价系统还是CTFC评价系统,比伐芦定组对于控制直接PCI术中发生慢血流/无复流发生的效果均不劣于普通肝素组(P>0.05)。患者住院期间资料分析显示,比伐芦定组在不增加血小板数目降低风险的基础上能够获得较高的活化凝血时间(ACT)值(P<0.001)。随访30 d及1年结果显示两组MACE、NACE事件发生率比较,差异均无统计学意义(均P>0.05)。结论比伐芦定对急性心肌梗死患者直接PCI治疗具有较好的临床疗效及安全性且不增加直接PCI术中慢血流/无复流发生。

关键词(KeyWords)： 比伐芦定;普通肝素;急性心肌梗死;经皮冠状动脉介入治疗

Abstract:

Keywords:

基金项目(Foundation): 中国医师协会探索心血管研究基金项目(DFCMDA201417);; 辽宁省科学技术计划项目(2015020433)

作者(Author): 顾崇怀,赵昕,邓宇阳,荆全民,王效增,马颖艳,刘海伟,徐凯,王斌,韩雅玲

参考文献(References)：

• [1]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南.中华心血管病杂志,2015,43(5):675-690.
• [2]Mehran R,Pocock SJ,Nikolsky E,et al.A risk score to predict bleeding in patients with acute coronary syndromes.J Am Coll Cardiol,2010,55(23):2556-2566.
• [3]Lincoff AM,Bittl JA,Harrington RA,et al.Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention:REPLACE-2 randomized trial.JAMA,2003,289(7):853-863.
• [4]Stone GW,Ware JH,Bertrand ME,et al.Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management:one-year results from the ACUITY trial.JAMA,2007,298(21):2497-2506.
• [5]Mehran R,Lansky AJ,Witzenbichler B,et al.Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction(HORIZONS-AMI):1-year results of a randomised controlled trial.Lancet,2009,374(9696):1149-1159.
• [6]杨晓旭,赵昕,韩雅玲,等。比伐芦定对急性冠状动脉综合征患者行经皮冠状动脉介入治疗的单中心疗效观察.中国介入心脏病学杂志,2015;23(9):481-486.
• [7]Ma YC,Zuo L,Chen JH,et al.Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease.J Am Soc Nephrol,2006,17(10):2937-2944.
• [8]Van de Werf F,Bax J,Betriu A,et al.Management of acute myocardial infarction in patients presenting with persistent STsegment elevation:the Task Force on the Management of STSegment Elevation Acute Myocardial Infarction of the European Society of Cardiology.Eur Heart J,2008,29(23):2909-2945.
• [9]洪涛.冠状动脉TIMI血流分级.中国介入心脏病学杂志,2003,11(3):154.
• [10]Ding S,Pu J,Qiao ZQ,et al.TIMI myocardial perfusion frame count:a new method to assess myocardial perfusion and its predictive value for short-term prognosis.Catheter Cardiovasc Interv,2010,75(5):722-732.
• [11]Mehran R,Rao SV,Bhatt DL,et al.Standardized bleeding definitions for cardiovascular clinical trials:a consensus report from the Bleeding Academic Research Consortium.Circulation,2011,123(23):2736-2747.
• [12]Brosh D,Assali AR,Mager A,et al.Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality.Am J Cardiol,2007,99(4):442-445.
• [13]De Luca G,Verdoia M,Suryapranata H.Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty:a metaanalysis of 8 randomized trials.Atherosclerosis,2012,222(2):426-433.
• [14]Deibele AJ,Jennings LK,Tcheng JE,et al.Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function:the Intracoronary Eptifibatide(ICE)Trial.Circulation,2010,121(6):784-791.
• [15]Umemura S,Nakamura S,Sugiura T,et al.The effect of verapamil on the restoration of myocardial perfusion and functional recovery in patients with angiographic no-reflow after primary percutaneous coronary intervention.Nucl Med Commun,2006,27(3):247-254.
• [16]Migliorini A,Stabile A,Rodriguez AE,et al.Comparison of Angio Jet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction.The JETSTENT trial.J Am Coll Cardiol,2010,56(16):1298-1306.
• [17]Han YL,Guo J,Zheng Y,et al.Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction:the BRIGHT randomized clinical trial.JAMA,2015,313(13):1336-1346.
• [18]Shahzad A,Kemp I,Mars C,et al.Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention(HEAT-PPCI):an open-label,single centre,randomised controlled trial.Lancet,2014,384(9957):1849-1858.
• [19]Windecker S,Kolh P,Alfonso F,et al.2014 ESC/EACTS Guidelines on myocardial revascularization:The Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC)and the European Association for CardioThoracic Surgery(EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI).Eur Heart J,2014,35(37):2541-2619.